CAR-T 細胞療法市場按目標抗原、治療用途、地區-規模、份額、前景和機會分析2022-2030

CAR-T 細胞療法是一種利用免疫 T 細胞消滅癌症的免疫療法。 CAR-T細胞療法也被稱為細胞基因療法，因為它修飾了T細胞的基因。 CAR-T 細胞療法使用一種稱為白細胞去除術的方法從體內去除 T 細胞。 提取的 T 細胞被稱為 CAR-T 細胞，因為它們通過添加特定的嵌合抗原受體 (CAR) 基因進行修飾。 CAR-T 細胞通過引入特定的嵌合抗原受體 (CAR) 基因進行修飾，然後擴增並註射到體內。 各種類型的 CAR-T 細胞療法旨在對抗某些類型的癌症。 CAR-T細胞是為每位患者定制的，並註入血液中。 CAR-T細胞療法被用作抗癌的新基因療法。 各種臨床和臨床前研究正在進行中，以研究各種 CAR-T 細胞療法對特定癌症的安全性和有效性。 還有一些政府舉措旨在提高人們對癌症的認識，包括美國疾病控制和預防中心 (CDC) 開展的教育活動。

市場動態

市場上的主要參與者越來越多地採用有機策略，例如產品批准，預計這將在預測期內推動市場增長。 例如，2022年5月，全球醫療保健公司諾華公司宣布美國食品和藥物管理局批准Kymriah（tisagenlecleucel）CAR-T細胞療法用於治療成人復發或難治性濾泡性淋巴瘤患者，並獲得批准。 該批准基於對 II 期臨床試驗中 68% 響應率的評估。

這項研究的主要特點

• 本報告對全球 CAR-T 細胞療法市場進行了深入分析，顯示了以 2021 年為基準年的預測期 (2022-2030) 的市場規模和復合年增長率 (CAGR%)。
• 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
• 它還提供重要的見解，例如市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略。
• 根據公司亮點、產品組合、主要亮點、財務業績和戰略等參數介紹全球 CAR-T 細胞療法市場主要參與者的概況。
• 本研究涵蓋的主要公司包括 Bristol-Myers Squibb Company、Johnson & Johnson Services, Inc.、Novartis AG、CARsgenTherapeutics Co.,Ltd、Aurora Biopharma、Legend Biotech、Gilead Sciences, Inc.、Pfizer Inc. ., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics 等知名企業
• 這份報告中的見解將使企業營銷人員和高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 《全球 CAR-T 細胞療法市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球 CAR-T 細胞療法市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按目標抗原分類
  • 市場概況：按治療應用分類
  • 市場概況：按地區
• 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 市場機會
• 影響分析
• 市場趨勢
• 近期趨勢
• 收購和合作場景
• 監管場景
• 管道分析
• 害蟲分析
• 搬運工分析

第 4 章 CAR-T 細胞療法的全球市場 - COVID-19 影響分析

• 總體影響
• 對供需的影響
• COVID-19 對市場的影響

第 5 章全球 CAR-T 細胞療法市場：按目標抗原分類，2017-2030

• CD19
• BCMA
• HER2
• GD2
• CD20
• CD22
• CD30
• CD33
• HER1
• 其他（CLDN18 等）

第 6 章全球 CAR-T 細胞療法市場：按治療用途分類，2017-2030

• 急性淋巴細胞白血病
• 慢性淋巴細胞白血病
• 瀰漫性大 B 細胞淋巴瘤 (DLBCL)
• 濾泡性淋巴瘤
• 套細胞淋巴瘤
• 多發性骨髓瘤
• 膠質母細胞瘤
• 肉瘤
• 神經母細胞瘤
• 急性髓性白血病
• 乳腺癌
• 胰腺癌
• 肝細胞癌
• 結腸癌
• 其他（胃癌等）

第 7 章全球 CAR-T 細胞療法市場：按地區劃分，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲地區
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第八章競爭格局

• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Novartis AG
• CARsgenTherapeutics Co.,Ltd
• Aurora Biopharma
• Legend Biotech
• Gilead Sciences, Inc.
• Pfizer Inc.
• bluebird bio, Inc.
• Sorrento Therapeutics, Inc.
• Mustang Bio
• Fate Therapeutics

第 9 章

• 調查方法
• 關於出版商

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.

Key features of the study:

• This report provides in-depth analysis of the global CAR T cell therapy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global CAR T cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global CAR T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market

Detailed Segmentation:

• Global CAR T Cell Therapy Market, By Targeted Antigen:
  • CD19
  • BCMA
  • HER2
  • GD2
  • CD20
  • CD22
  • CD30
  • CD33
  • HER1
  • Others (CLDN18, etc.)
• Global CAR T Cell Therapy Market, By Therapeutic Application:
  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Glioblastoma
  • Sarcoma
  • Neuroblastoma
  • Acute Myeloid Leukemia
  • Breast Cancer
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Others (Gastric Cancer, etc.)
• Global CAR T Cell Therapy Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • CARsgenTherapeutics Co., Ltd
  • Aurora Biopharma
  • Legend Biotech
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • bluebird bio, Inc.
  • Sorrento Therapeutics, Inc.
  • Mustang Bio
  • Fate Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Targeted Antigen
  • Market Snapshot, By Therapeutic Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Regulatory Scenario
• Pipeline Analysis
• PEST Analysis
• Porter's Analysis

4. Global CAR T Cell Therapy Market- COVID-19 Impact Analysis

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global CAR T Cell Therapy Market, By Targeted Antigen, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• CD19
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• BCMA
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• HER2
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• GD2
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD20
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD22
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD30
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD33
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• HER1
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (CLDN18, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global CAR T Cell Therapy Market, By Therapeutic Application, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Acute Lymphocytic Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Chronic Lymphocytic Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Diffuse Large B-cell Lymphoma (DLBCL)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Follicular Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Mantle Cell Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Multiple Myeloma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Glioblastoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Sarcoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Neuroblastoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Acute Myeloid Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Pancreatic Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Hepatocellular Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Colorectal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (Gastric Cancer, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global CAR T Cell Therapy Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Johnson & Johnson Services, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CARsgenTherapeutics Co.,Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aurora Biopharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Legend Biotech
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• bluebird bio, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sorrento Therapeutics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mustang Bio
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Fate Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us